6 d. ago "Can't Hold Post Permanently": DKS Hints At Quitting Big Congress Post

Senior Congress leader DK Shivakumar injected fresh life Wednesday into his tug-of-war with Siddaramaiah - over the post of Karnataka Chief Minister - hinting he might quit as boss of the party's...

Politics

1 week ago Granules India Q2 Review: Dolat Capital Maintains 'Add', Hikes Target Price

Any escalation of the warning letter on the Gagillapur facility to an import alert will lead to a downgrade in its earnings and rating, adds Dolat Capital.

Events

1 week ago Alkem Labs Q2 Review: Dolat Capital Upgrades EPS Estimate For FY26

Dolat Capital upgrades Alkem Labs' FY26E/FY27E EPS estimates by 3.5%/6.0%, assuming higher sales and Ebitda margin.

Politics

1 week ago Surya Roshni Q2 Review: IDBI Capital Maintains 'Hold' On Muted Earnings

IDBI Capital cuts its FY26E/FY27E Ebitda estimates by 14%/1% and maintains 'Hold' rating on Surya Roshni.

Politics

2 w. ago Finolex Industries Q2 Review: IDBI Capital Maintains 'Hold' Post A Mixed Bag Quarter

IDBI Capital believes despite near-term challenges, Finolex Industries is poised to outperform the peers given its strong brand recall, capacity addition and healthy balance sheet.

Politics

2 w. ago Cummins India Q2 Review: IDBI Capital Downgrades To 'Hold' As Valuations Catch Up With Growth

IDBI Capital revises its stance on Cummins India from Buy to Hold, citing that valuations have caught up with growth prospects, despite strong quarterly performance.

Politics

2 w. ago NCC Q2 Review: Execution Delays Drag Performance, Says IDBI Capital Maintaining Buy

IDBI Capital maintains a 'BUY' rating on NCC and revises target price, valuing the stock at 12x FY27E EPS.

Politics

2 w. ago Castrol India Q3 Review: IDBI Capital Maintains 'Hold', Sees Limites Upside

Castrol's rich valuations limit potential upside, so IDBI Capital recommends investors to await a better entry point in the stock.

Politics

3 w. ago 'Hold' Jubilant Pharmova Shares Maintains Systematix Post Inline Q2 Results

Jubilant Pharmova's sterile CMO and allergy Immunotherapy posts strong growth in Q2.

Politics

3 w. ago Manappuram Finance Q2 Review: Dolat Capital Maintains 'Reduce' But Hikes Target Price

Bain Capital's strategic investment is expected to bring operational excellence, governance strength, and deeper capital access across NBFC verticals.

Economics

4 w. ago 'Sell' Sagar Cements Shares Maintains Dolat Capital Post Muted Q2 Results, Revises Target Price

Dolat Capital maintains 'Sell' rating on Sagar Cements with revised target price based on 7.0x consolidated FY28E EV/Ebitda.

Events

4 w. ago Justice Surya Kant in line to be next Chief Justice, 1st Haryanvi to hold post

Justice Surya Kant in line to be next Chief Justice, 1st Haryanvi to hold post  India Today

Politics

last month Coforge Q2 Review: IDBI Capital Maintains 'Buy', Hikes Target Price

Coforge's distinctive AI-led solutions, including proprietary platforms across automation and software engineering, fuel its ongoing enterprise transformation work and margin expansion.

Economics